Neutrexin

NeuTrexin®

Trimetrexate glucuronate, see there.

Neutrexin

A brand name for TRIMETREXATE.
References in periodicals archive ?
a publicly held pharmaceutical company involved in the development and marketing of chemotherapeutic agents, from 1987 to 1998 where he took three products, Ethyol, Neutrexin and Hexalen, through development and regulatory approval in the US, Europe, Canada and other countries.
the main products are synagis, cytogam, respigam, ethyol, neutrexin and hexalen.
The company believes that sales of NeuTrexin and Hexalen were negatively affected during the second quarter by transitional factors relating to the assumption of full responsibility for promotion of these products in the United States by U.
Addressing another major clinical and regulatory objective, Clarke remarked that NeuTrexin is currently indicated for the treatment of pneumocystis carinii pneumonia, an opportunistic infection associated with AIDS, and stated that the company is conducting two Phase III clinical trials of NeuTrexin in combination with 5-FU and leucovorin, the current standard of care for treatment of patients with colorectal cancer.
Ethyol represents the company's third NDA approval, preceded by Hexalen and NeuTrexin which have been launched in the U.
The company has two compounds marketed in the United States: Hexalen(R) (altretamine) for the treatment of ovarian cancer, and NeuTrexin (trimetrexate glucuronate for injection) for the treatment of moderate- to-severe Pneumocystis carinii pneumonia, as well as a broad spectrum of drugs in various stages of development.
Second quarter sales of NeuTrexin reflect patient usage, net of the first quarter stocking activities.
The reductions in Hexalen and NeuTrexin sales were affected, the company believes, by the commitment of sales and marketing resources to the launch and ongoing promotion of Ethyol in the United States.
She further commented, "The use of NeuTrexin complete course IV-therapy allows for structured patient monitoring within the treatment specifications established as part of a homehealth program.
Sales of the company's other drug products, Hexalen(R) and NeuTrexin(R), were reduced from the prior year period due to the commitment of sales and marketing resources to the launch of Ethyol in the United States, to new product competitive pressures affecting sales of Hexalen, and to a reduction in the incidence and severity of Pneumocystis carinii pneumonia (PCP) in patients infected with the human immunodeficiency virus (HIV), affecting sales of NeuTrexin.
The larger loss for the first quarter of 1994 is due principally to increased research and development costs, where personnel expenses, support activities for clinical trials, and license and product registration fees rose; increased expenses associated with a new manufacturing facility in Nijmegen, The Netherlands; and higher marketing expenditures supporting the commercial launch of NeuTrexin.
Research and development costs increased due to higher personnel and clinical trial expenses reflecting the company's Phase III clinical programs for Ethyol in radiation protection and NeuTrexin in colorectal cancer.